Investors are always looking for stocks that are poised to beat at earnings season and ImmunoGen, Inc. (IMGN) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because ImmunoGen is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings—with the most up-to-date information possible—is a pretty good indicator of some favorable trends underneath the surface for IMGN in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 31 cents per share for IMGN, compared to a broader Zacks Consensus Estimate of a loss of 36 cents per share. This suggests that analysts have very recently bumped up their estimates for IMGN, giving the stock a Zacks Earnings ESP of 13.89% heading into earnings season.
— Zacks Investment Research